TD Asset Management Inc Has $19.93 Million Position in Natera, Inc. $NTRA

Key Points

• TD Asset Management Inc increased its stake in Natera, Inc. by 12.8% during Q2, bringing its total holdings to approximately $19.93 million.
• Natera's Q2 earnings report revealed a loss of ($0.74) per share, which was worse than analysts' expectations, despite the company experiencing 32.2% revenue growth year-over-year.
• Multiple institutional investors have significantly increased their positions in Natera, with Price T Rowe Associates boosting its stake by 56.3% and UBS AM increasing by 140.4% in the first quarter.

TD Asset Management Inc raised its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 12.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 117,948 shares of the medical research company's stock after buying an additional 13,402 shares during the quarter. TD Asset Management Inc owned 0.09% of Natera worth $19,926,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in shares of Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. Nuveen LLC acquired a new stake in Natera during the first quarter valued at approximately $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after purchasing an additional 732,156 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after purchasing an additional 660,538 shares during the period. Finally, Ninety One UK Ltd raised its holdings in shares of Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company's stock worth $95,111,000 after buying an additional 336,985 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Stock Performance

Natera stock opened at $181.69 on Friday. The business's fifty day moving average is $168.19 and its two-hundred day moving average is $158.35. The firm has a market cap of $24.94 billion, a P/E ratio of -95.13 and a beta of 1.74. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $187.34.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business's quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NTRA. Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Barclays reiterated an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. Finally, Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $196.81.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $132.89, for a total transaction of $398,670.00. Following the transaction, the insider owned 123,059 shares of the company's stock, valued at approximately $16,353,310.51. This represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 14,083 shares of Natera stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00. Following the completion of the sale, the chief executive officer directly owned 154,072 shares of the company's stock, valued at $24,651,520. This trade represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock valued at $10,963,125 over the last ninety days. Company insiders own 5.63% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.